Skip to main content

Table 1 Correlation between PRL-3 gene amplification and clinicopathological variables in 77 patients with gastric cancer

From: Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer

  

PRL-3 gene amplification

 

Variables

Total number

Negativity

Positivity

pvalue

  

Number

(%)

Number

(%)

 

PRL-3 expression

     

0.006

Negativity

37

37

(100)

0

(0)

 

Positivity

40

32

(80)

8

(20)

 

Age (years)

     

0.726

<60

34

30

(88)

4

(12)

 

≥60

43

39

(91)

4

(9)

 

Gender

     

0.710

Male

51

45

(88)

6

(12)

 

Female

26

24

(92)

2

(8)

 

Lymphatic permeation

     

0.343

Absence

15

15

(100)

0

(0)

 

Presence

62

54

(87)

8

(13)

 

Vascular permeation

     

0.263

Absence

25

24

(96)

1

(4)

 

Presence

52

45

(87)

7

(13)

 

Differentiation

     

0.134

Well and moderate

31

30

(97)

1

(3)

 

Poor

46

39

(85)

7

(15)

 

Depth of invasion

     

0.006*

T1 (m and sm)

15

15

(100)

0

(0)

 

T2 (mp and ss)

35

33

(94)

2

(6)

 

T3 (se)

19

16

(84)

3

(16)

 

T4 (si)

8

5

(63)

3

(38)

 

Lymph node metastasis

     

0.022

Absence

29

29

(100)

0

(0)

 

Presence

48

40

(83)

8

(17)

 

JCGC lymph node status†

     

0.004*

N0

29

29

(100)

0

(0)

 

N1

21

20

(95)

1

(5)

 

N2

20

14

(70)

6

(30)

 

N3 and distant lymph nodes

7

6

(86)

1

(14)

 

UICC lymph node status‡

     

0.002*

N0

29

29

(100)

0

(0)

 

N1

18

17

(94)

1

(6)

 

N2

16

13

(81)

3

(19)

 

N3 and distant lymph nodes

14

10

(71)

4

(29)

 

JCGC stage

     

0.005*

I (IA and IB)

20

20

(100)

0

(0)

 

II

20

20

(100)

0

(0)

 

III (IIIA and IIIB)

19

15

(79)

4

(21)

 

IV

18

14

(78)

4

(22)

 

UICC stage

     

0.003*

I (IA and IB)

21

21

(100)

0

(0)

 

II

20

20

(100)

0

(0)

 

III (IIIA and IIIB)

16

13

(81)

3

(19)

 

IV

20

15

(75)

5

(25)

Â